MARKET NEWS AND UPDATES.
Get notified for Latest News and Market Alerts.
Get notified for Latest News and Market Alerts.
×
The ratings continue to reflect the extensive experience of promoters in the pharmaceutical industry, and healthy financial risk profil
The company had raised funds amounting to Rs126.48 crore through the Issue of Equity Shares on a Preferential basis in January, 2022.
The company allotted 4959999 equity shares of the face value of Rs10 each at a premium of Rs245 per share under the preferential issue.
Kopran Research Laboratories is a wholly-owned subsidiary of the company.
Kopran subsidiary had stopped production operations from July 22, 2021, due to non-availability of electricity supply, water supply, an
Due to the onset of the second wave of the Pandemic, the expansion work was delayed, especially because of non-availability of Workers
The ratings continue to reflect the extensive experience of promoters in the pharmaceutical industry.
Throughout the trading session, Kopran stock surged till an intraday high of Rs40.85 per piece.
All the manufacturing units of the company were kept in functioning mode during the lockdown since pharmaceuticals are in the category
S&P BSE Healthcare index is currently trading in red, down by 19.08 points or 0.12%.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
